media – Page 6 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

【EXPERT Q&A】How to optimize the process of pharmaceutical trade?

Drugdu.com expert’s response: Optimizing the pharmaceutical trade process is a crucial measure to enhance the efficiency of the pharmaceutical supply chain, reduce costs, and ensure the quality and safety of pharmaceutical products. Below are some specific optimization strategies: I. Digital and Information Technology Upgrading Implement ERP Systems: Functions: Integrate modules such as procurement, inventory, sales, and finance to achieve real-time data sharing and process automation. Advantages: Improve data processing efficiency, reduce human errors, and enhance decision-making support capabilities. Apply Blockchain Technology: Functions: Ensure the traceability of pharmaceutical products from production to sale, recording information at every stage. Advantages: Enhance pharmaceutical safety, boost consumer trust, and facilitate regulatory oversight. Utilize Big Data Analytics: Functions: Analyze data on market demand, sales trends, inventory levels, etc. Advantages: Optimize procurement plans, reduce inventory backlogs, and improve capital turnover rates. II. Supply Chain Collaboration and Integration Establish Strategic Partnerships: Methods: Form long-term and stable cooperative ...
- Source: drugdu
- 103
- June 27, 2025
RUSSIAN HEALTH CARE WEEK

Organiser: Informa Markets Time：December 8 – December 11, 2025 address：Krymskiy val, 10, Moscow 119049, Russia Exhibition hall：Central House of Artists Product range: Diagnostic Equipment: X-ray diagnostic equipment, ultrasonic diagnostic equipment, functional examination devices, endoscopic examination equipment, nuclear medicine equipment, laboratory diagnostic equipment, pathological diagnostic equipment, imaging devices for diagnosis, chromatographic analyzers, clinical laboratory analyzers, dialysis and transplantation surgery-related equipment. Therapeutic Equipment: Clinical radiological equipment; clinical laboratory equipment and reagents, ward care equipment, surgical equipment, radiotherapy equipment, nuclear medicine therapeutic equipment, physicochemical equipment, laser equipment, dialysis treatment equipment, cryogenic equipment for therapeutic purposes, emergency rescue equipment. Auxiliary Equipment: Disinfection and sterilization equipment, refrigeration equipment, central suction and oxygen supply systems, air conditioning equipment, pharmaceutical machinery and equipment, blood bank equipment, medical data processing equipment, medical video and photography equipment, medical air extraction systems, cosmetic and plastic surgery equipment; ophthalmic equipment, treatment technologies, and materials; dental equipment and instruments, dental prosthetic systems ...
- Source: drugdu
- 111
- June 26, 2025
【EXPERT Q&A】How exactly does the improvement of medical detection technology help discover more potential diseases?

Drugdu.com expert’s response: The advancement of medical detection technologies enables the discovery of more potential diseases through various means, which are specifically reflected in the following aspects: High-Sensitivity Detection Technologies: High-sensitivity detection methods can detect minute changes in biomarkers at an earlier stage. For instance, high-sensitivity troponin detection technology can identify the release of troponin during the early phase of myocardial cell injury, thereby supporting the early diagnosis of acute coronary syndrome and myocardial infarction. This technology can uncover early lesions that might be missed by traditional methods. Multimodal Data Fusion and Comprehensive Analysis: By integrating data from multiple detection modalities, such as electrocardiograms (ECGs), echocardiograms, and blood tests, medical detection technologies can provide more comprehensive health information. This multimodal data fusion enhances diagnostic accuracy and helps identify potential disease risks that might be overlooked by a single detection method. Artificial Intelligence (AI) and Big Data Analytics: AI technologies can ...
- Source: drugdu
- 113
- June 25, 2025
Multitasking ctDNA Helps Guide Lymphoma Treatment

Circulating tumor DNA (ctDNA) is gaining ground as an important multitasking tool in the frontline treatment of diffuse large B-cell lymphoma (DLBCL), with key novel applications that include identifying genetic subtypes and guiding the escalation or de-escalation of chemotherapy, new research has shown. “We have demonstrated that a PET/ctDNA-guided approach in frontline DLBCL is feasible in a multicenter setting,” said first author Anastasios Stathis, MD, of the Clinic of Hematology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland, in presenting the findings at the 18th International Conference on Malignant Lymphoma (ICML) 2025 in Lugano, Switzerland. “The allocation of patients and treatment based on the combined results of PET and ctDNA is operationally successful,” he said. The findings are from the preliminary results of the phase 2 SAKK 38/19 trial, which focuses on the goal of identifying patients with key MCD genetic subtypes that are known to respond poorly to the ...
- Source: drugdu
- 103
- June 24, 2025
Healthy gut microbiome before chemo could help protect breast cancer patients against cardiotoxicity

New research suggests that a healthy microbiome before chemotherapy could help protect breast cancer patients against heart damage, or cardiotoxicity, as a result of cancer therapy. Researchers found that specific bacteria in patients’ gut microbiome correlated with heart health biomarkers that suggest they are at greater risk of heart damage during chemotherapy. “To allow cancer survivors healthier lives, we need to find new ways to protect them from the long-term side-effects of chemotherapy. This study is one of the first to ask whether the microbiome could play a role in how well patient’s hearts fare during chemotherapy,” explained Doctor Athos Antoniades, Head of Research and Development at Stremble Ventures LTD who is leading the multi-omics, including the gut microbiome DNA sequencing for this project. “We saw a clear association between some specific genus of gut bacteria and cardiac biomarkers that suggest patients are at greater risk of heart damage during ...
- Source: drugdu
- 143
- June 24, 2025
The application for the new drug for ADHD has been accepted, bringing new hope to millions of children with the disease

Recently, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced that the New Drug Application (NDA) of Shanghai Aike Baifa’s new drug Dexmethylphenidate Dexmethylphenidate Compound Capsules for the treatment of attention deficit hyperactivity disorder (ADHD) has been officially accepted. In April, the drug was included in the priority review by CDE. This means that this highly anticipated innovative ADHD drug is expected to significantly shorten the review cycle and enter the market ahead of schedule. ADHD is not simply “naughty and hyperactive”. As a chronic neurodevelopmental disorder, it is characterized by an imbalance in the transmission of neurotransmitters in the brain, which makes it difficult for patients to concentrate and control behavioral impulses. According to titration data, in 2021, the number of children aged 6-17 in China exceeded 24 million, with a prevalence of 1.7%. However, for a long time, clinical drug ...
- Source: drugdu
- 111
- June 24, 2025
Fierce battle for acetylcysteine tablets! Huayi Pharmaceutical’s entry accelerates market differentiation

On June 17, according to the latest announcement on the CDE official website: Huayi Pharmaceutical’s application for the listing of the Class 3 generic drug acetylcysteine tablets was accepted, making it the eighth Chinese pharmaceutical company to enter this dosage form. This move has caused new waves in the acetylcysteine market. from Tidu , the sales of acetylcysteine tablets in all terminals have been growing in recent years. In 2024, the sales of all terminals exceeded 389 million yuan, a year-on-year increase of more than 13%. In the entire expectorant market, acetylcysteine has topped the list for four consecutive years with a share of over 50%. Acetylcysteine tablets are a commonly used expectorant in clinical practice. By decomposing the disulfide bonds of mucin in sputum, it effectively reduces the viscosity of sputum and promotes the discharge of sputum. In clinical practice, it is mainly used to treat symptoms such as ...
- Source: drugdu
- 114
- June 24, 2025
Lianya Pharmaceuticals opens up a new path to accelerate the export of domestic high-end preparations and domestic supply

The quality of drug preparations is directly related to the life, health and treatment effects of hundreds of millions of patients. At present, China is the world’s second largest pharmaceutical market. It is reported that the total output value of China’s pharmaceutical industry will reach about 3.8 trillion yuan in 2022, and generic drugs will dominate the Chinese pharmaceutical market, accounting for more than 60%. However, in the field of high-end generic drugs, especially in sustained-release preparations and complex injections, there are high technical barriers, and the market accessibility of domestic high-end generic preparations is relatively low. The root cause is the weakness of the core production process, especially the precise control of the drug release mechanism, the application of complex excipient systems, and the precision quality control technology in large-scale production, which has become a key bottleneck restricting domestic high-end preparations from achieving equivalence with original research drugs and ...
- Source: drugdu
- 115
- June 24, 2025
Guangzhou International High-end Medical Devices Exhibition

Organiser: China Association for Medical Devices Industry (CAMDI) Time：July 17 – 19, 2025 address：No. 1108, Yingbin Avenue, Baiyun District, Guangzhou City, Guangdong Province Exhibition hall：Guangzhou Airport Expo Center Product range: Medical Imaging: CT, DR, medical X-ray systems, ultrasonic diagnostic instruments, magnetic resonance equipment, tumor treatment machines, medical films and processing systems, medical 3D printing devices, etc. Remote, Mobile, and Intelligent Monitoring Medical Devices: Sleep monitors, remote ECG, blood pressure, blood oxygen, and body temperature detectors, cloud blood pressure meters, Bluetooth blood pressure and blood glucose monitors, wearable medical devices, and health kiosks; Mobile Medical: Telemedicine, APPs, big data cloud platforms, physical examination, rehabilitation, and medical diagnostic and treatment equipment. Diagnostic and Therapeutic Equipment: Endoscopic systems, otorhinolaryngological instruments, dynamic analysis instruments, cryogenic freezing equipment, dialysis treatment equipment, emergency rescue equipment, etc. Surgical Instruments: Electrosurgical units and consumables, staplers, suture devices, suture needles/threads, laser surgical instruments, ultrasonic surgical devices, equipment and ...
- Source: drugdu
- 112
- June 24, 2025
Zhengda Tianqing’s bispecific ADC is approved for clinical trials, and the competition for EGFR/c-Met targets heats up again

Recently, the official website of the Center for Drug Evaluation (CDE) of the China National Drug Administration showed that the TQB6411 injection, a Class 1 innovative drug independently developed by Zhengda Tianqing, has been approved for clinical use and is intended to be used to treat patients with advanced malignant tumors. As a dual-antibody ADC (antibody-drug conjugate) targeting EGFR/c-Met, this drug has become a “new species” that has not yet been approved for marketing in the world. The design logic of TQB6411 directly targets the key pain points of tumor treatment – drug resistance and compensatory activation of signal pathways. Epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (c-Met) are driver genes for various tumors such as lung cancer and colorectal cancer, and often form synergistic effects in signal transduction. When a drug inhibits only one of the pathways, the other pathway may be compensatorily activated, resulting in ...
- Source: drugdu
- 81
- June 23, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.